Y-mAbs Therapeutics Engages Investors at Upcoming Conferences
This September, Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a key player in the biopharmaceutical industry, is poised to attract investor interest. The company is known for its innovative radioimmunotherapy and antibody-based treatments designed to transform cancer care. Michael Rossi, the energetic CEO of Y-mAbs, will be at the forefront of presentations at two significant investor conferences, highlighting the company's pioneering strategies in oncology.
Key Conferences Scheduled for September
The first event on the agenda is the Morgan Stanley 22nd Annual Global Healthcare Conference, which will be held on September 6, 2024, at 1:50 p.m. ET. This session will feature an engaging fireside chat that allows investors to gain insights directly from the leadership team. Following that, Y-mAbs will take part in the Cantor Global Healthcare Conference on September 17, 2024, at 3:40 p.m. ET, also featuring a fireside chat aimed at fostering in-depth discussions and investor engagement.
Live Webcasts and Archived Sessions
For those who cannot attend in person, Y-mAbs is dedicated to ensuring accessibility. Live webcasts of both presentations will be streamed on the company's investor relations website, with recordings available for at least 30 days afterward. This effort reflects Y-mAbs' commitment to keeping stakeholders updated on its progress in cancer treatment.
About Y-mAbs and Its Innovative Therapies
Y-mAbs Therapeutics is at the cutting edge of biopharmaceutical innovation, providing promising therapies that leverage immunotherapy for cancer treatment. The company’s advanced technologies include the Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and unique bispecific antibodies developed through the Y-BiClone technology. A highlight of their product pipeline is DANYELZA® (naxitamab-gqgk), the first FDA-approved therapy for patients dealing with relapsed or refractory high-risk neuroblastoma.
Commitment to Cancer Treatment
Y-mAbs is deeply focused on research and development, striving to offer essential solutions for patients with limited treatment options. By participating in these conferences, the company not only piques investor interest but also raises awareness about its groundbreaking therapies. Their commitment to combating cancer goes beyond business; it’s a mission that has a direct impact on lives.
Investor Relationship Stronghold
Engaging with investors is crucial for any company aiming to thrive in competitive markets. The leadership team at Y-mAbs recognizes this importance and is enthusiastic about sharing the company's journey, vision, and the advancements in their promising pipeline. The CEO's direct presentations provide opportunities for both potential and current investors to ask relevant questions and understand the strategic direction of Y-mAbs.
Contact Information for Investors
For further inquiries, investors can reach out to Courtney Dugan, VP and Head of Investor Relations, at cdu@ymabs.com.
Frequently Asked Questions
What is Y-mAbs Therapeutics known for?
Y-mAbs Therapeutics specializes in developing radioimmunotherapy and antibody-based therapies aimed at treating cancer, particularly neuroblastoma.
When will Y-mAbs present at investor conferences?
Y-mAbs will present at the Morgan Stanley Conference on September 6, 2024, and at the Cantor Conference on September 17, 2024.
How can investors access the conference presentations?
Investors can access live webcasts of the presentations on Y-mAbs' investor relations website, with recordings available for 30 days afterward.
What notable therapy does Y-mAbs offer?
Y-mAbs offers DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for high-risk neuroblastoma patients who have had insufficient responses to prior therapies.
How can investors contact Y-mAbs for more information?
Investors can contact Courtney Dugan at cdu@ymabs.com for inquiries about the company and its investor relations.
